217 related articles for article (PubMed ID: 32414618)
1. Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?
Marra G; Calleris G; Alessio P; Oderda M; Palou J; Joniau S; Piechaud T; Smelzo S; Morlacco A; Sharma V; Tilki D; Van der Poel H; Veerman H; Karnes RJ; Gontero P
Eur Urol Focus; 2021 Jul; 7(4):807-811. PubMed ID: 32414618
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
4. Salvage Radical Prostatectomy in Nonmetastatic Castration-Resistant Prostate Cancer.
López-Fontana G; Guglielmi JM; López-Fontana R; Hinojosa-Jury ML; López-Fontana C; López-Laur JD
Arch Esp Urol; 2022 Sep; 75(7):638-641. PubMed ID: 36214146
[TBL] [Abstract][Full Text] [Related]
5. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
[TBL] [Abstract][Full Text] [Related]
6. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
Saito T; Matsumoto K; Kosaka T; Yasumizu Y; Tanaka N; Takeda T; Morita S; Mizuno R; Asanuma H; Oya M
Int J Clin Oncol; 2023 May; 28(5):707-715. PubMed ID: 36929093
[TBL] [Abstract][Full Text] [Related]
7. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
8. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
9. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Tanaka N; Takeda T; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
World J Urol; 2020 Jul; 38(7):1749-1756. PubMed ID: 31559475
[TBL] [Abstract][Full Text] [Related]
10. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
11. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
12. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
13. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
14. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy.
Komori T; Matsumoto K; Kosaka T; Takeda T; Kamitani R; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Asanuma H; Oya M
Ann Surg Oncol; 2023 Oct; 30(11):6936-6942. PubMed ID: 37418130
[TBL] [Abstract][Full Text] [Related]
16. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract][Full Text] [Related]
17. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
[TBL] [Abstract][Full Text] [Related]
18. Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy.
Kodama H; Koie T; Oikawa M; Narita T; Tanaka T; Noro D; Iwamura H; Tobisawa Y; Yoneyama T; Hashimoto Y; Ohyama C
Int Urol Nephrol; 2020 Apr; 52(4):671-679. PubMed ID: 31897875
[TBL] [Abstract][Full Text] [Related]
19. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of salvage radical prostatectomy following more than one failed local therapy.
Sivaraman A; Scardino P; Eastham J
Investig Clin Urol; 2018 May; 59(3):152-157. PubMed ID: 29744471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
